New Product? Or Just Another Version of Noritate?
Galderma USA Announces New Product for the Topical Treatment of Rosacea
Innovative Product Offers a New Treatment Alternative for 14 Million American Sufferers
FORT WORTH, Texas, July 5 /PRNewswire/ -- Galderma Laboratories, L.P. today announces FDA approval of an exciting new product for the topical treatment of the inflammatory lesions of rosacea. MetroGel® (metronidazole) Topical Gel, 1% will be available by prescription July 29, 2005. The new medication incorporates a higher concentration of metronidazole in a new, technologically advanced vehicle.
One advantage of MetroGel® 1% is the vehicle, incorporating HSA-3(TM), a combination of niacinamide, betadex and propylene glycol. The vehicle is a water-based formulation and contains no alcohol. Another advantage of the new product is that it allows for once-a-day dosing as opposed to twice-a-day for most other topical rosacea treatments.
"Rosacea is the fourth most common diagnosis made by dermatologists(1), and we expect that MetroGel® 1% will eventually become the number one prescribed topical rosacea treatment," said Scott McCrea, Galderma product manager. Galderma brand MetroGel® 0.75% is currently the market leader in topical prescription rosacea treatment(2).
Albert Draaijer, president of Galderma Laboratories, L.P. said, "The development and approval of MetroGel® 1% shows Galderma's ongoing commitment to research and development of new treatments, for rosacea and other dermatological disease. We will continue to focus all of our resources on dermatology."
Innovative Product Offers a New Treatment Alternative for 14 Million American Sufferers
FORT WORTH, Texas, July 5 /PRNewswire/ -- Galderma Laboratories, L.P. today announces FDA approval of an exciting new product for the topical treatment of the inflammatory lesions of rosacea. MetroGel® (metronidazole) Topical Gel, 1% will be available by prescription July 29, 2005. The new medication incorporates a higher concentration of metronidazole in a new, technologically advanced vehicle.
One advantage of MetroGel® 1% is the vehicle, incorporating HSA-3(TM), a combination of niacinamide, betadex and propylene glycol. The vehicle is a water-based formulation and contains no alcohol. Another advantage of the new product is that it allows for once-a-day dosing as opposed to twice-a-day for most other topical rosacea treatments.
"Rosacea is the fourth most common diagnosis made by dermatologists(1), and we expect that MetroGel® 1% will eventually become the number one prescribed topical rosacea treatment," said Scott McCrea, Galderma product manager. Galderma brand MetroGel® 0.75% is currently the market leader in topical prescription rosacea treatment(2).
Albert Draaijer, president of Galderma Laboratories, L.P. said, "The development and approval of MetroGel® 1% shows Galderma's ongoing commitment to research and development of new treatments, for rosacea and other dermatological disease. We will continue to focus all of our resources on dermatology."
posted by Madison at 10:27 AM
<< Home